(3R,5R)-3-((benzylthio)methyl)-3-methyl-5-phenylmorpholin-2-one | 950672-64-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (3R,5R)-3-((benzylthio)methyl)-3-methyl-5-phenylmorpholin-2-one
• 英文别名: (3R,5R)-3-benzylsulfanylmethyl-3-methyl-5-phenyl-morpholin-2-one；(3R,5R)-3-(benzylsulfanylmethyl)-3-methyl-5-phenylmorpholin-2-one
• CAS: 950672-64-7
• 化学式: C₁₉H₂₁NO₂S
• 分子量: 327.447
• InChiKey: HUQKETMNDVHIDK-HKUYNNGSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3R,5R)-3-((benzylthio)methyl)-3-methyl-5-phenylmorpholin-2-one 在 氨 、 lithium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 49.17h， 生成 (R)-5-(benzylthiomethyl)-1-((R)-2-hydroxy-1-phenylethyl)-5-methylimidazolidine-2,4-dione
  参考文献：
  名称：

  Stereoselective synthesis of a dialkylhydantoin featuring an asymmetric Strecker reaction on an acyclic dialkyl ketone

  摘要：

  A diastereoselective Strecker reaction using (R)-(-)-phenylglycinol forms the basis of a concise scalemic route to dialkylhydantoin 1. The phenylglycinol functionality was exploited in the manipulation of the aminonitrile Strecker product through to the dialkylhydantoin via a short, efficient sequence involving crystalline intermediates. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.02.008
• 作为产物：
  描述：

  (R)-2-benzylsulfanylmethyl-2-methyl-4-phenyl-oxazolidine 在 盐酸 、 magnesium bromide ethyl etherate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 30.75h， 生成 (3R,5R)-3-((benzylthio)methyl)-3-methyl-5-phenylmorpholin-2-one
  参考文献：
  名称：

  Stereoselective synthesis of a dialkylhydantoin featuring an asymmetric Strecker reaction on an acyclic dialkyl ketone

  摘要：

  A diastereoselective Strecker reaction using (R)-(-)-phenylglycinol forms the basis of a concise scalemic route to dialkylhydantoin 1. The phenylglycinol functionality was exploited in the manipulation of the aminonitrile Strecker product through to the dialkylhydantoin via a short, efficient sequence involving crystalline intermediates. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.02.008

文献信息

• Novel Crystal Modifications
  申请人：Briggner Lars-Erik

  公开号：US20090221640A1

  公开（公告）日：2009-09-03

  Novel crystal modifications of (5S)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonylmethyl]-5-methyl-imidazolidine-2,4-dione are disclosed together with processes for preparing such modifications, pharmaceutical compositions comprising such a modification, and the use of such a modification in therapy.

  本发明公开了(5S)-5-[4-(5-氯吡啶-2-氧基)-哌啶-1-磺酰甲基]-5-甲基咪唑烷-2,4-二酮的新颖晶体修饰，以及制备该修饰的过程、包含该修饰的药物组合物，以及在治疗中使用该修饰的方法。
• WO2007/106022
  申请人：——

  公开号：——

  公开（公告）日：——
• A NEW CRYSTALLINE FORM G OF (5S)-5-[4-(5-CHLORO-PYRIDIN-2-YLOXY)-PIPERIDINE-1-SULFONYL-METHYL]-5-METHYL-IMIDAZOLIDINE-2,4-DIONE (I) AND INTERMEDIATES THEREOF.
  申请人：AstraZeneca AB

  公开号：EP2064202A2

  公开（公告）日：2009-06-03
• [EN] NOVEL CRYSTAL MODIFICATIONS<br/>[FR] NOUVELLES FORMES CRISTALLINES
  申请人：ASTRAZENECA AB

  公开号：WO2007106022A2

  公开（公告）日：2007-09-20

  [EN] Novel crystal modifications of (5S)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonylmethyl]-5-methyl-imidazolidine-2,4-dione are disclosed together with processes for preparing such modifications, pharmaceutical compositions comprising such a modification, and the use of such a modification in therapy.
  [FR] La présente invention concerne de nouvelles formes cristallines de la (5S)-5-[4-(5-chloro-pyridin-2-yloxy)-pipéridine-1-sulfonylméthyl]-5-méthyl-imidazolidine-2,4-dione ainsi que des procédés de synthèse de telles formes, des compositions pharmaceutiques les incluant et leurs applications en thérapie.